# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Irène Joliot-Curie (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB003-SYN-TD
- Date: 1955-09-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Solène Marchand-Ellis, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Genetic results, classification and risk, fitness for treatment, and the start of induction. **S**

## History of present illness

Mrs. Joliot-Curie returns twelve days after the marrow biopsy to review the genetic results and decide on treatment. She has had blood counts twice a week; she felt better after the red cell transfusion but is tired again and now rests for part of each afternoon and has stopped going to the laboratory. No fever, bleeding beyond bruising, or infection. She had her echocardiogram, lung function tests and ECG earlier today. Her hepatitis B, hepatitis C and HIV tests were negative, and she is not immune to hepatitis B. She has read the trial reports on the treatment options and has questions. She met the palliative care team this morning. **S**

| Element | Detail |
|---|---|
| Symptoms | Tired, resting in the afternoons, off work; no fever |
| Results | Cytogenetics and molecular panel; echocardiogram; lung function; ECG |
| Infection screen | Hepatitis B, hepatitis C and HIV negative; not immune to hepatitis B |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; resting in the afternoons; no fever |
| Respiratory | Positive | Breathless on one flight of stairs; no cough |
| Integumentary | Positive | Bruises fading; no new ones |
| Psychiatric | Positive | Anxious about the results; sleeping six hours; PHQ-9 8, GAD-7 8 |

4 systems reviewed. **S**

## Current medications

- Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycle **S**
- Venetoclax 10 mg oral tablet, cycle 1: 10 mg on day 1 and 20 mg on day 2, then two tablets (20 mg) daily with the 50 mg tablet from day 4 (70 mg a day, reduced for posaconazole) **S**
- Venetoclax 50 mg oral tablet, cycle 1: one tablet alone on day 3 (50 mg), then one tablet daily with two 10 mg tablets from day 4 (70 mg a day) **S**
- Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic **S**
- Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxis **S**
- Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5 **S**
- Allopurinol 300 mg oral tablet, one tablet daily for tumor lysis prophylaxis during cycle 1 **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/70 mmHg; pulse 92 bpm; respirations 16/min; temperature 36.9 °C; oxygen saturation 97% on room air; weight 53.5 kg; BMI 20.1 kg/m². All vital signs are synthetic.

White cell count: 1.6 10*3/uL (low); Absolute neutrophil count: 0.4 10*3/uL (low); Hemoglobin: 8.6 g/dL (low); Platelets: 18 10*3/uL (low); Blood blasts (smear): 16% (high); Sodium: 140 mmol/L; Potassium: 4.1 mmol/L; Creatinine: 0.8 mg/dL; eGFR: 85 mL/min/1.73 m²; Calcium: 9.1 mg/dL; Phosphate: 3.6 mg/dL; Uric acid: 5.8 mg/dL; LDH: 448 U/L (high); ALT: 24 U/L; Total bilirubin: 0.7 mg/dL; DLCO, percent predicted: 58% (low); FEV1, percent predicted: 76% (low); Left ventricular ejection fraction: 62%; QTc (ECG): 428 ms; ECOG performance status: 2; PHQ-9: 8; GAD-7: 8. All results are synthetic.

## Change since baseline

- White cell count: 2.1 10*3/uL (low) at baseline, 1.6 10*3/uL (low) at this visit **S**
- Absolute neutrophil count: 0.6 10*3/uL (low) at baseline, 0.4 10*3/uL (low) at this visit **S**
- Hemoglobin: 8.4 g/dL (low) at baseline, 8.6 g/dL (low) at this visit **S**
- Platelets: 38 10*3/uL (low) at baseline, 18 10*3/uL (low) at this visit **S**
- Blood blasts (smear): 12% (high) at baseline, 16% (high) at this visit **S**
- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4 mmol/L at baseline, 4.1 mmol/L at this visit **S**
- Creatinine: 0.78 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- eGFR: 88 mL/min/1.73 m² at baseline, 85 mL/min/1.73 m² at this visit **S**
- Calcium: 9.2 mg/dL at baseline, 9.1 mg/dL at this visit **S**
- Uric acid: 6.4 mg/dL (high) at baseline, 5.8 mg/dL at this visit **S**
- LDH: 412 U/L (high) at baseline, 448 U/L (high) at this visit **S**
- ALT: 22 U/L at baseline, 24 U/L at this visit **S**
- Total bilirubin: 0.6 mg/dL at baseline, 0.7 mg/dL at this visit **S**
- ECOG performance status: 1 at baseline, 2 at this visit **S**
- PHQ-9: 5 at baseline, 8 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Tired, alert and composed; weight 53.5 kg; ECOG 2 |
| Mouth | No ulcers, thrush or gum swelling |
| Respiratory | Fine crackles at the right apex; otherwise clear |
| Abdomen | No enlarged liver or spleen |
| Skin | Fading bruises |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Acute myeloid leukemia with mutated TP53 and a complex karyotype; ELN 1951 adverse risk** (C92.00). Cytogenetics show a complex karyotype with loss of chromosome 5q material and of chromosome 7 (45,XX,del(5)(q14q34),-7,-17,+mar in 16 of 20 cells), and the molecular panel shows a TP53 mutation at a variant allele frequency of 41 percent, with no NPM1, FLT3, IDH1, IDH2 or CEBPA mutation. By the WHO 1951 classification this is AML, myelodysplasia-related (defined by the complex karyotype); by the ICC 1951 it is AML with mutated TP53. Neither system's post-cytotoxic-therapy (therapy-related) label applies, because that label requires earlier chemotherapy or radiotherapy given as treatment, whereas her exposure was occupational; we record the leukemia as following occupational exposure to ionizing radiation, and its genetics are those typical of radiation-associated and therapy-related myeloid neoplasms. ELN 1951 genetic risk is adverse. Fitness: ECOG 2 and a DLCO of 58 percent of predicted (HCT-CI score 3) make her ineligible for intensive induction under the VIALE-A criteria; intensive chemotherapy also gives poor results in TP53-mutated AML. After discussing the options, including intensive induction and clinical trials (none open to her here), she chooses azacitidine with venetoclax, aiming for remission and an allogeneic transplant. Dr. Engquist-Mensah's team will lead treatment. **S**
   - Admit today for cycle 1: azacitidine 115 mg (75 mg/m2) on days 1 to 7; venetoclax 10 mg on day 1, 20 mg on day 2, 50 mg on day 3, then 70 mg daily from day 4, the dose with posaconazole.
   - Tumor lysis monitoring during the ramp-up, with allopurinol and fluids.
   - Bone marrow on day 21 to 28.
   - Transplant center evaluation and unrelated donor search now.
2. **Reduced lung gas transfer from old tuberculous scarring** (R94.2). DLCO 58 percent and FEV1 76 percent of predicted. The echocardiogram is normal (ejection fraction 62 percent) and the QTc 428 ms. **S**
   - Counts toward her transplant comorbidity index; repeat lung function before transplant.
3. **Occupational exposure to ionizing radiation** (Z57.1). Records not yet received. **S**
   - Chase the written request.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with differential and smear | At diagnosis; two to three times a week during induction; before each cycle | Completed today | White cells 1.6, neutrophils 0.4, hemoglobin 8.6 g/dL after one unit, platelets 18 x10^3/uL, blasts 16% |
| Laboratory | Bone marrow: morphology, flow cytometry, cytogenetics, molecular panel | At diagnosis; day 21 to 28 of cycle 1; then as response and transplant planning require | Completed today | Complex karyotype with del(5q), -7 and -17; TP53 mutation, VAF 41%; no NPM1, FLT3, IDH1, IDH2 or CEBPA mutation: WHO 1951 AML, myelodysplasia-related; ICC 1951 AML with mutated TP53; ELN 1951 adverse |
| Laboratory | Chemistry: electrolytes, creatinine, calcium, phosphate, uric acid, LDH, liver tests | At diagnosis; during venetoclax ramp-up for tumor lysis; then weekly in cycle 1 and before each cycle | Completed today | Sodium 140, potassium 4.1 mmol/L; creatinine 0.80 mg/dL, eGFR 85; calcium 9.1, phosphate 3.6, uric acid 5.8 mg/dL; LDH 448 U/L; ALT 24 U/L, bilirubin 0.7 mg/dL; tumor lysis labs every 6 to 8 hours in hospital during the ramp-up |
| Imaging | Fitness: performance status, comorbidity (HCT-CI), echocardiogram, lung function | Before choosing induction | Completed today | ECOG 2; DLCO 58% and FEV1 76% of predicted; ejection fraction 62%; HCT-CI 3: unfit for intensive induction by the VIALE-A criteria |
| Medication safety | Azole safety: posaconazole interactions (venetoclax dose), liver tests, QTc, trough level | At start; liver tests weekly; trough level after about a week of dosing; QTc with any added QT-prolonging drug | Completed today | Baseline QTc 428 ms and liver tests normal; venetoclax set at 70 mg for posaconazole, a strong CYP3A inhibitor |
| Medication safety | Transfusion support: thresholds, irradiated and leukoreduced products | At each blood count | Completed today | No transfusion needed today; irradiated, leukoreduced products flagged in the blood bank |
| Self-management | Infection prophylaxis and the fever plan | Throughout neutropenia | Completed today | Posaconazole, acyclovir and levofloxacin start today; fever plan reviewed |
| Laboratory | Hepatitis B, hepatitis C and HIV testing before therapy | Once, before therapy | Completed today | Hepatitis B surface antigen, core antibody and surface antibody negative; hepatitis C and HIV negative: no hepatitis B prophylaxis needed |
| Referral | HLA typing and allogeneic transplant evaluation | At diagnosis | Completed today | HLA typing complete; transplant center evaluation and unrelated donor search started |
| Referral | Specialist palliative care: symptoms, prognosis, goals and values | From diagnosis, at every visit | Completed today | First palliative care visit this morning: symptoms, her understanding of the prognosis, and her goals |
| Survey | Distress, depression and anxiety screening | At diagnosis and at each phase of treatment | Completed today | PHQ-9 8, GAD-7 8: mild; supported by the palliative care team |
| Self-management | Occupational exposure history and dose records | Until the records are received | Due | Written request sent; records awaited |

## Goal progress

- Diagnosis, classification and a treatment decision within two weeks of the first visit. Outcome by 1955-09-28: Marrow two days after the first visit; genetics back and treatment started on day 14. **S**
- Complete cycle 1 without tumor lysis, invasive fungal infection, or bleeding. In progress; target 1955-10-30. **S**
- Remission on the response assessment after cycle 1 (ELN 1951 complete remission, or complete remission with partial hematologic recovery). In progress; target 1955-10-30. **S**
- Her own goals and values recorded and her symptoms controlled with the palliative care team from the first cycle. Outcome by 1955-09-28: Seen by the palliative care team on day 1; goals recorded; symptoms reviewed at every visit. **S**
- Her occupational dose records obtained and the exposure history documented. In progress; target 1955-10-30. **S**

## Medication changes

- Started: Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycle **S**
- Started: Venetoclax 10 mg oral tablet, cycle 1: 10 mg on day 1 and 20 mg on day 2, then two tablets (20 mg) daily with the 50 mg tablet from day 4 (70 mg a day, reduced for posaconazole) **S**
- Started: Venetoclax 50 mg oral tablet, cycle 1: one tablet alone on day 3 (50 mg), then one tablet daily with two 10 mg tablets from day 4 (70 mg a day) **S**
- Started: Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic **S**
- Started: Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxis **S**
- Started: Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5 **S**
- Started: Allopurinol 300 mg oral tablet, one tablet daily for tumor lysis prophylaxis during cycle 1 **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026), National Comprehensive Cancer Network
- Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022 (PMID 35797463) (2022), European LeukemiaNet (Blood)
- Khoury JD, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022 (PMID 35732831) (2022), World Health Organization (Leukemia)
- Arber DA, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022 (PMID 35767897) (2022), International Consensus Classification (Blood)
- DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (VIALE-A). N Engl J Med 2020 (PMID 32786187) (2020), New England Journal of Medicine
- NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026), National Comprehensive Cancer Network
- Taplitz RA, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: ASCO and IDSA Clinical Practice Guideline Update (PMID 29461916) (2018), American Society of Clinical Oncology and Infectious Diseases Society of America (Journal of Clinical Oncology)
- Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024 (PMID 38748941) (2024), American Society of Clinical Oncology
- Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA 2023 (PMID 37824153) (2023), Association for the Advancement of Blood and Biotherapies (JAMA)
- Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015), AABB (Annals of Internal Medicine)
- Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (PMID 32716741) (2020), American Society of Clinical Oncology
- 10 CFR 19.13, Notifications and reports to individuals (radiation exposure reports on request) (2026), U.S. Nuclear Regulatory Commission (Electronic Code of Federal Regulations)
- 29 CFR 1910.1096, Ionizing radiation (records of exposure and disclosure to employees) (2026), Occupational Safety and Health Administration
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- In hospital for the venetoclax ramp-up, then twice-weekly blood counts with transfusion as needed. Bone marrow on day 21 to 28. Palliative care and transplant center visits during cycle 1. Emergency department at once for a temperature of 38.0 °C or more. **S**
- Next scheduled visit 1955-10-19: day 22 of cycle 1: bone marrow response, transfusion and infection review, and stopping venetoclax for count recovery. **S**
